A pharmaceutical industry insider provides a breakdown of the differences between Ozempic and Wegovy, noting they are the same molecule (Semaglutide) but dosed differently for diabetes versus obesity. The source explains insurance hurdles, the "Ozempic face" phenomenon, and warns that compounding pharmacies are not sourcing their Semaglutide from the patent holder, Novo Nordisk.
